ProPhase Labs (PRPH) Competitors $0.29 +0.01 (+3.42%) Closing price 04/17/2025 03:59 PM EasternExtended Trading$0.28 -0.02 (-5.17%) As of 04/17/2025 05:56 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisChartCompetitorsDividendEarningsHeadlinesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock PRPH vs. GDTC, DARE, GBIO, PLUR, DRRX, CASI, LEXX, ATHE, CALC, and KALAShould you be buying ProPhase Labs stock or one of its competitors? The main competitors of ProPhase Labs include CytoMed Therapeutics (GDTC), Daré Bioscience (DARE), Generation Bio (GBIO), Pluri (PLUR), DURECT (DRRX), CASI Pharmaceuticals (CASI), Lexaria Bioscience (LEXX), Alterity Therapeutics (ATHE), CalciMedica (CALC), and KALA BIO (KALA). These companies are all part of the "pharmaceutical products" industry. ProPhase Labs vs. CytoMed Therapeutics Daré Bioscience Generation Bio Pluri DURECT CASI Pharmaceuticals Lexaria Bioscience Alterity Therapeutics CalciMedica KALA BIO ProPhase Labs (NASDAQ:PRPH) and CytoMed Therapeutics (NASDAQ:GDTC) are both small-cap medical companies, but which is the better stock? We will compare the two companies based on the strength of their institutional ownership, earnings, media sentiment, analyst recommendations, community ranking, valuation, profitability, dividends and risk. Which has preferable earnings and valuation, PRPH or GDTC? CytoMed Therapeutics has lower revenue, but higher earnings than ProPhase Labs. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioProPhase Labs$6.77M1.79-$16.78M-$1.26-0.23CytoMed TherapeuticsN/AN/A-$3.13MN/AN/A Is PRPH or GDTC more profitable? CytoMed Therapeutics has a net margin of 0.00% compared to ProPhase Labs' net margin of -217.64%. CytoMed Therapeutics' return on equity of 0.00% beat ProPhase Labs' return on equity.Company Net Margins Return on Equity Return on Assets ProPhase Labs-217.64% -62.92% -30.22% CytoMed Therapeutics N/A N/A N/A Which has more volatility and risk, PRPH or GDTC? ProPhase Labs has a beta of -0.56, suggesting that its stock price is 156% less volatile than the S&P 500. Comparatively, CytoMed Therapeutics has a beta of -0.26, suggesting that its stock price is 126% less volatile than the S&P 500. Does the media favor PRPH or GDTC? In the previous week, ProPhase Labs had 2 more articles in the media than CytoMed Therapeutics. MarketBeat recorded 2 mentions for ProPhase Labs and 0 mentions for CytoMed Therapeutics. CytoMed Therapeutics' average media sentiment score of 0.00 beat ProPhase Labs' score of -1.00 indicating that CytoMed Therapeutics is being referred to more favorably in the news media. Company Overall Sentiment ProPhase Labs Negative CytoMed Therapeutics Neutral Do analysts prefer PRPH or GDTC? CytoMed Therapeutics has a consensus price target of $5.00, suggesting a potential upside of 103.25%. Given CytoMed Therapeutics' stronger consensus rating and higher probable upside, analysts clearly believe CytoMed Therapeutics is more favorable than ProPhase Labs.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score ProPhase Labs 0 Sell rating(s) 0 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 0.00CytoMed Therapeutics 0 Sell rating(s) 0 Hold rating(s) 1 Buy rating(s) 0 Strong Buy rating(s) 3.00 Does the MarketBeat Community favor PRPH or GDTC? ProPhase Labs received 110 more outperform votes than CytoMed Therapeutics when rated by MarketBeat users. However, 100.00% of users gave CytoMed Therapeutics an outperform vote while only 48.93% of users gave ProPhase Labs an outperform vote. CompanyUnderperformOutperformProPhase LabsOutperform Votes11448.93% Underperform Votes11951.07% CytoMed TherapeuticsOutperform Votes4100.00% Underperform VotesNo Votes Do institutionals and insiders hold more shares of PRPH or GDTC? 9.4% of ProPhase Labs shares are owned by institutional investors. Comparatively, 0.0% of CytoMed Therapeutics shares are owned by institutional investors. 20.7% of ProPhase Labs shares are owned by company insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryCytoMed Therapeutics beats ProPhase Labs on 10 of the 15 factors compared between the two stocks. Get ProPhase Labs News Delivered to You Automatically Sign up to receive the latest news and ratings for PRPH and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart PRPH vs. The Competition Export to ExcelMetricProPhase LabsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$12.15M$6.44B$5.30B$7.34BDividend YieldN/A3.23%5.12%4.30%P/E Ratio-0.236.8921.8617.80Price / Sales1.79230.57380.5497.75Price / CashN/A65.6738.2634.64Price / Book0.115.936.453.98Net Income-$16.78M$142.99M$3.22B$247.81M7 Day Performance-6.00%4.43%2.85%1.80%1 Month Performance-25.83%-12.72%-8.67%-6.81%1 Year Performance-94.67%-9.42%11.46%1.31% ProPhase Labs Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)PRPHProPhase Labs0.5607 of 5 stars$0.29+3.4%N/A-95.4%$12.15M$6.77M-0.23130Short Interest ↑Negative NewsGDTCCytoMed Therapeutics2.0608 of 5 stars$2.35-1.5%$5.00+113.2%+18.8%$25.65MN/A0.00N/AGap DownDAREDaré Bioscience1.9372 of 5 stars$2.89-0.3%$24.00+730.4%-14.5%$25.58M$9,784.00-4.8930Short Interest ↓News CoverageGBIOGeneration Bio2.7832 of 5 stars$0.38+0.8%$7.33+1,853.5%-86.9%$25.16M$19.89M-0.17150PLURPluri1.0902 of 5 stars$3.58-2.2%N/A-24.1%$25.05M$678,000.00-0.64150Short Interest ↓News CoverageDRRXDURECT1.1532 of 5 stars$0.80+2.2%N/A-15.1%$24.83M$2.03M-1.3180Short Interest ↓Positive NewsCASICASI Pharmaceuticals4.0271 of 5 stars$2.01-3.8%$6.00+198.5%-9.8%$24.72M$28.54M-0.90180Short Interest ↓Gap DownLEXXLexaria Bioscience2.3234 of 5 stars$1.40-0.7%$7.00+400.0%-41.0%$24.57M$496,923.00-2.807Earnings ReportShort Interest ↑Gap DownATHEAlterity Therapeutics2.3487 of 5 stars$2.76-4.8%$12.00+334.8%+69.1%$24.47MN/A0.0010Short Interest ↓Gap UpCALCCalciMedica1.536 of 5 stars$1.81-0.5%$18.00+894.5%-62.9%$24.40MN/A-1.6830News CoveragePositive NewsGap UpKALAKALA BIO2.3061 of 5 stars$3.74-11.8%$15.00+301.1%-49.6%$24.13M$3.89M-0.3030 Related Companies and Tools Related Companies GDTC Competitors DARE Competitors GBIO Competitors PLUR Competitors DRRX Competitors CASI Competitors LEXX Competitors ATHE Competitors CALC Competitors KALA Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:PRPH) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersTrump’s Secret WeaponHave you looked at the stock market recently? Millions of investors are scrambling trying to figure out what's...American Alternative | SponsoredElon Reveals Why There Soon Won’t Be Any Money For Social SecurityElon Musk's Near-Death Experience Sparks Dire Warning for Americans After cheating death twice—once in a te...Colonial Metals | SponsoredTrump’s Bitcoin Reserve is No Accident…Bryce Paul believes this is the #1 coin to buy right now The catalyst behind this surge is a massive new b...Crypto 101 Media | Sponsored100-year-old investment secret predicts what?!A 100-year-old indicator has quietly predicted nearly every major market meltdown — including the Dot-Com Bust...Weiss Ratings | SponsoredThe first casualty of the 2025 trade warThe headlines scream tariffs and export bans — but the real damage is happening in retirement portfolios. Tim ...Investors Alley | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding ProPhase Labs, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share ProPhase Labs With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy PRPH Stock Free PRPH Stock Alerts